Elutia Inc. reported a 16% increase in fourth quarter revenue compared to the previous year.
The Company eliminated $26.9 million of secured debt during the quarter.
Elutia had total cash and escrowed proceeds of $44.3 million at the end of 2025.
NXT-41 Biomatrix Program
Elutia is developing NXT-41x, an antibiotic-eluting biomatrix, with the potential to improve outcomes in breast reconstruction.
Financial Performance
Preliminary net sales for Q4 2025 were $3.3 million, showing a 16% growth from Q4 2024. Debt repayment and a cash position of $36.3 million were also highlighted.
Development Milestones
The Company plans to submit an FDA filing for NXT-41 in the first half of 2026, with anticipated FDA clearance in the second half. FDA clearance for NXT-41x is expected in the first half of 2027.
- Elutia's success with EluPro paved the way for advancements in plastic and reconstructive surgery.
- The company's strong financial position and strategic focus on NXT-41x position it well to address the high complication rates in breast reconstruction.
With a solid financial foundation and promising developmental pipeline, Elutia is poised for continued growth and innovation in the medical technology space.